NCT03044587已完成2 期
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 93
- 试验地点
- 1
- 主要终点
- Progression-free survival [PFS]
研究概览
简要总结
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
详细描述
The primary objective is to determine whether a combination of 5-FU and nal-IRI prolongs progression-free survival in patients with locally advanced or metastatic adenocarcinoma of the biliary tract
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent incl. participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •Age ≥ 18 years at time of study entry
- •Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract
- •Protocol-specific staging guidelines have to be observed and non-resectability has to be confirmed by local tumor board
- •Measurable or assessable disease according to RECIST 1.1
- •ECOG performance status 0-1
- •Life expectancy of more than 3 months
- •If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration ≤ 2 x ULN
- •Adequate blood count, liver-enzymes, and renal function:
- •White blood cell count ≥ 3.5 x 10^6/mL
- •Platelet count ≥ 100 x 10^9/L (>100,000 per mm3)
- •AST (SGOT)/ALT (SGPT) ≤ 5 x institutional upper limit of normal
- •Serum Creatinine ≤ 1.5 x ULN and a calculated glomerular filtration rate ≥ 30 mL per minute
- •Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
- •No prior palliative chemotherapy for biliary tract cancer
- •No adjuvant treatment within 6 months prior to study entry
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
排除标准
- •Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes
- •Premalignant hematologic disorders, e.g. myelodysplastic syndrome
- •Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment
- •Prior (>5 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].
- •Pre-existing lung disease
- •History or clinical evidence of CNS metastases
- •Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
- •are asymptomatic and
- •have no requirement for steroids 6 weeks prior to start of study treatment. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
- •History of hypersensitivity to any of the study drugs or any of the constituents of the products
- •Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
- •Severe non-healing wounds, ulcers or bone fractions
- •Evidence of bleeding diathesis or coagulopathy
- •Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
- •Medication that is known to interfere with any of the agents applied in the trial.
- •Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessary (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum β-HCG) at Screening.
- •Known Gilbert-Meulengracht syndrome
- •Known chronic hypoacusis, tinnitus or vertigo
- •Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration.
- •Previous enrollment or randomization in the present study (does not include screening failure).
- •Any other chemotherapy at study start
- •Involvement in the planning and/or conduct of the study
- •Patient who might be dependent on the sponsor, site or the investigator
- •Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
- •Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
研究组 & 干预措施
Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
Experimental
Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
干预措施: Arm NaI-IRI + 5-FU + Leucovorin (Arm A) (Drug)
Arm Cisplatin + Gemcitabine (Arm B, standard of care)
Other
Cisplatin, Gemcitabine Cycle q3w
干预措施: Arm Cisplatin + Gemcitabine (Arm B) (Drug)
结局指标
主要结局
Progression-free survival [PFS]
时间窗: approx. 25 months
次要结局
- Toxicity/Safety according to CTC-AE-criteria(approx. 54 months)
- Health related quality of life(approx. 54 months)
- Retrospective correlation of resectability in accordance with a central surgical board compared to local surgical review(approx. 54 months)
- Retrospective central radiological review(approx. 54 months)
- Disease control rate according to RECIST 1.1(approx. 54 months)
- Objective tumor response rate (ORR) according to RECIST 1.1(approx. 54 months)
- Overall progression free survival according to RECIST 1.1(approx. 54 months)
- 3-years overall survival(approx. 36 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Combination of Nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil alone in patients with cholangio- and gallbladder cancer previously treated with gemcitabine-based therapiesadvanced, unresectable and metastatic cholangio- and gallbladder carcinomaMedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10017634Term: Gallbladder neoplasms malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10051667Term: Metastases to gallbladderSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10017614Term: Gallbladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003709-33-DEAIO-Studien-gGmbH100
已完成
2 期
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based TherapiesCholangiocarcinoma Non-resectableCholangiocarcinoma MetastaticCholangiocarcinoma of the GallbladderCholangiocarcinoma AdvancedNCT03043547AIO-Studien-gGmbH100
进行中（未招募）
1 期
al-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancerocally advanced or metastatic, non resectable, adenocarcinoma of the biliary tract including intrahepatic and extrahepatic bile ductMedDRA version: 21.1Level: LLTClassification code 10025734Term: Malignant neoplasm of biliary tract, part unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10028982Term: Neoplasm biliary tractSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002467-34-DEAIO-Studien-gGmbH92
进行中（未招募）
1 期
Phase 1b trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.metastatic colorectal cancerMedDRA version: 27.0Level: LLTClassification code: 10052362Term: Metastatic colorectal cancer Class: 10029104MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2024-515580-64-00Fondazione IRCCS Istituto Nazionale Dei Tumori18
招募中
3 期
Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer2024-518143-38-00Fondation Franc.Cancerologie Digestive288